Gerber Kawasaki Wealth & Investment Management trimmed its stake in shares of Idexx Laboratories (NASDAQ:IDXX) by 25.5% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 1,200 shares of the company’s stock after selling 410 shares during the quarter. Gerber Kawasaki Wealth & Investment Management’s holdings in Idexx Laboratories were worth $229,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in IDXX. Bank of Montreal Can raised its holdings in shares of Idexx Laboratories by 7.1% during the 4th quarter. Bank of Montreal Can now owns 377,944 shares of the company’s stock worth $59,103,000 after buying an additional 24,943 shares in the last quarter. National Pension Service raised its holdings in shares of Idexx Laboratories by 4.3% during the 4th quarter. National Pension Service now owns 95,376 shares of the company’s stock worth $14,915,000 after buying an additional 3,935 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Idexx Laboratories by 1,000.0% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock worth $172,000 after buying an additional 1,000 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in shares of Idexx Laboratories by 98.1% during the 4th quarter. State of Alaska Department of Revenue now owns 14,375 shares of the company’s stock worth $2,247,000 after buying an additional 7,120 shares in the last quarter. Finally, Conestoga Capital Advisors LLC raised its holdings in shares of Idexx Laboratories by 22.6% during the 4th quarter. Conestoga Capital Advisors LLC now owns 13,911 shares of the company’s stock worth $2,175,000 after buying an additional 2,560 shares in the last quarter. Hedge funds and other institutional investors own 87.72% of the company’s stock.
In other Idexx Laboratories news, Director William T. End sold 9,470 shares of the company’s stock in a transaction dated Thursday, May 10th. The stock was sold at an average price of $208.36, for a total value of $1,973,169.20. Following the sale, the director now owns 31,786 shares in the company, valued at approximately $6,622,930.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lawrence D. Kingsley purchased 1,000 shares of Idexx Laboratories stock in a transaction on Wednesday, February 14th. The stock was bought at an average price of $178.05 per share, for a total transaction of $178,050.00. Following the transaction, the director now directly owns 4,558 shares in the company, valued at approximately $811,551.90. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 16,444 shares of company stock valued at $3,276,328. Insiders own 2.56% of the company’s stock.
A number of equities analysts have recently commented on the company. Zacks Investment Research cut Idexx Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, April 3rd. Canaccord Genuity reissued a “buy” rating and set a $210.00 price target on shares of Idexx Laboratories in a report on Monday, January 29th. BidaskClub raised Idexx Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th. Piper Jaffray boosted their price target on Idexx Laboratories to $211.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Finally, Stifel Nicolaus upped their target price on Idexx Laboratories from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, May 7th. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $201.43.
Shares of Idexx Laboratories opened at $210.88 on Tuesday, according to MarketBeat Ratings. Idexx Laboratories has a 12-month low of $209.95 and a 12-month high of $212.68. The company has a quick ratio of 0.72, a current ratio of 0.96 and a debt-to-equity ratio of -12.43. The stock has a market capitalization of $18.36 billion, a price-to-earnings ratio of 60.05, a PEG ratio of 2.51 and a beta of 0.60.
Idexx Laboratories (NASDAQ:IDXX) last issued its earnings results on Friday, May 4th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.09. Idexx Laboratories had a negative return on equity of 530.24% and a net margin of 13.87%. The business had revenue of $537.60 million during the quarter, compared to analysts’ expectations of $525.14 million. During the same quarter in the prior year, the firm earned $0.77 EPS. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. research analysts forecast that Idexx Laboratories will post 4.16 earnings per share for the current fiscal year.
About Idexx Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Idexx Laboratories (NASDAQ:IDXX).
Receive News & Ratings for Idexx Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.